About the Company
aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $APTO News
NeuroBo Phase 2a study for MASH drug to proceed as planned
NeuroBo (NRBO) said a safety review committee has recommended that a Phase 2a study of its drug candidate DA-1241 for the treatment of MASH continue without any modifications.
Which Is a Better Investment, Apellis Pharmaceuticals Inc or Avidity Biosciences Inc Stock?
Learn more about whether Apellis Pharmaceuticals Inc or Avidity Biosciences Inc is a better investment based on AAII's A+ ...
EQB: Stocks Undervalued by Analyst Consensus on TSX (EQB)
EQB Inc is among the group of undervalued stocks on the Toronto Stock Exchange. This means the consensus value for each stock on this list is above its current price. This report is generated monthly.
Avidity Biosciences: Strong Buy Rating Amidst Positive Clinical Developments and Price Target Surge
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on RNA stock, giving a Buy rating on March 4. Joseph Schwartz has ...
Morguard: Stocks Undervalued by Analyst Consensus on TSX (MRC)
Morguard Corp is among the group of undervalued stocks on the Toronto Stock Exchange. This means the consensus value for each stock on this list is above its current price.
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates
Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago. These ...
Loading the latest forecasts...